Back to list

Gilead-Lupus Membranous Nephropathy

University of North Carolina at Chapel Hill


Description

To evaluate the efficacy of filgotinib and GS-9876 (both oral medications) in treating LMN (class V lupus nephritis)


Keywords:

Lupus


Category:

Drug or Biologic
Phase:2

Qualifications

 


Age
18 - 75 years


Gender
Any


Study Population

Male or female patients between 18 and 75 years of age, with active lupus membranous nephropathy who are not in partial or complete remission in response to treatment with one or more anti-inflammatory or immunosuppresive agents


Investigator

Vimal Derebail
Assistant Professor
Medicine-Nephrology

For questions, contact:

Brenda Meier
brenda_meier@med.unc.edu
(919) 445-2430


Recruitment Period End

December 31, 2019

Location

Primary Location
Clinical & Translational Research Center (CTRC)
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA
Secondary Location
N/A

Study Qualifications

Gender Any

Age Range 18 - 75 years

Participant qualification(s) -Kidney biopsy within the past 36 months with a diagnosis of active Class V (membranous) lupus nephritis -Urine protein excretion of at least 1.5 grams -Prior treatment with at least one immunosuppressive therapy (i.e. cyclosporin, tacrolimus, cyclophosphamide, azathioprine, cellcept (mycophenolate mofetil), methotrexate, leflunomide, moderate to high-dose steroids)

Not eligible if: -Use of rituximab within 6 months of enrollment -History of, or current, inflammatory or autoimmune disease other than SLE -live vaccine within 30 days of Day 1

Number of Visits

    » 18 In person visit(s)

    1 screening, 17 study visits at the research center (CTRC)

    » 0 Remote visit(s)

Participation Period

1 year

Compensation

$50 per completed study visit

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.